How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Ruxience is given by a doctor or nurse, not picked up at a pharmacy.

What to do

  1. Ask your care team or your plan what you’d pay before your visit.

Your care team and your insurance decide which product you get.

Compare every option

Brand name

Ruxience, the original

Cash priceAsk the pharmacy
Ways to save on Ruxience

The maker’s card

Pfizer Oncology Together Co-Pay Savings Program for Injectables / Pfizer enCompass Co-Pay Assistance Program for RUXIENCE

Savings card from Pfizer

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a dose

The card takes up to $4,000–$10,000 a year off your co-pay.

Sign up on pfizercopay.com 

Or call 1-800-555-4820.

In the maker’s words

“as little as $0 per administered dose.”

From the maker’s offer on pfizercopay.com, checked November 17, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized generic

There isn’t one.

Not soldThere isn’t one

Regular generic

Ruxience is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

Not soldAsk the pharmacy

What it’s used for

What the FDA label says

RUXIENCE is a CD20-directed cytolytic antibody indicated for the treatment of:

  • Adult patients with Non-Hodgkin's Lymphoma (NHL).
    • Relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent.
    • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
    • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
    • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.
  • Adult patients with Chronic Lymphocytic Leukemia (CLL).
    • Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
  • Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to-severely-active RA who have inadequate response to one or more TNF antagonist therapies.
  • Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids.
  • Moderate to severe Pemphigus Vulgaris (PV) in adult patients.

Source: the FDA label for Ruxience (Pfizer Laboratories Div Pfizer Inc), October 2, 2026. Full label on DailyMed 

Good to know

  • “Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
  • Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
  • Don’t stop or change a medicine without talking to your pharmacist or prescriber.